- Home
- BE vs TFX Comparison
BE vs TFX Comparison
Compare BE & TFX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BE
- TFX
- Stock Information
- Founded
- BE 2001
- TFX 1943
- Country
- BE United States
- TFX United States
- Employees
- BE N/A
- TFX N/A
- Industry
- BE Industrial Machinery/Components
- TFX Medical/Dental Instruments
- Sector
- BE Energy
- TFX Health Care
- Exchange
- BE Nasdaq
- TFX Nasdaq
- Market Cap
- BE 5.1B
- TFX 5.1B
- IPO Year
- BE 2018
- TFX N/A
- Fundamental
- Price
- BE $45.28
- TFX $120.70
- Analyst Decision
- BE Buy
- TFX Hold
- Analyst Count
- BE 17
- TFX 9
- Target Price
- BE $27.26
- TFX $141.57
- AVG Volume (30 Days)
- BE 12.6M
- TFX 549.9K
- Earning Date
- BE 07-31-2025
- TFX 07-31-2025
- Dividend Yield
- BE N/A
- TFX 1.12%
- EPS Growth
- BE N/A
- TFX N/A
- EPS
- BE 0.10
- TFX 4.18
- Revenue
- BE $1,630,054,000.00
- TFX $3,041,342,000.00
- Revenue This Year
- BE $21.86
- TFX $3.50
- Revenue Next Year
- BE $21.05
- TFX $5.33
- P/E Ratio
- BE $440.09
- TFX $29.10
- Revenue Growth
- BE 22.72
- TFX 1.11
- 52 Week Low
- BE $9.02
- TFX $108.90
- 52 Week High
- BE $47.16
- TFX $249.91
- Technical
- Relative Strength Index (RSI)
- BE 81.14
- TFX 55.48
- Support Level
- BE $41.42
- TFX $115.85
- Resistance Level
- BE $46.50
- TFX $123.09
- Average True Range (ATR)
- BE 3.01
- TFX 3.47
- MACD
- BE 0.64
- TFX 0.90
- Stochastic Oscillator
- BE 86.83
- TFX 73.99
About BE Bloom Energy Corporation
Bloom Energy designs, manufactures, sells, and installs solid-oxide fuel cell systems ("Energy Servers") for on-site power generation. Bloom Energy Servers are fuel-flexible and can use natural gas, biogas, and hydrogen to create 24/7 electricity for stationary applications. In 2021, the company announced plans to leverage its technology and enter the electrolyzer market. Bloom primarily sells its systems in the United States and internationally.
About TFX Teleflex Incorporated
Teleflex is a Wayne, Pennsylvania-based manufacturer of hospital supplies and medical devices primarily in the bloodstream/vascular and surgical areas. The firm reports results across seven segments: vascular access (24% of 2024 sales), interventional (19%), anesthesia (13%), surgical (15%), interventional urology (11%), original-equipment manufacturing (11%), and other (7%). Geographic exposure for the business is primarily in the US, which accounts for 60% of revenue, with international markets making up the remainder.